OPK (opko.com) Business Value to Revenue

Public company logo of OPKO Health (OPK)

Efficient courier delivery of biomaterials guarantees the diagnostic accuracy of OPKO Health, Inc. (OPK). Business success is based on the restructuring of BioReference and Rayaldee sales. Stability is ensured by the absence of sanctions and American standards. The GURU.Markets service features a line chart showing the EV/Sales history, where the parameter reaches 2633.10, clearly demonstrating the dynamics of the company's valuation relative to revenue.

OPKO Health - OPK EV/Sales Multiple (period 11/23/2025 - 11/20/2026)

OPK (OPKO Corp): analytical breakdowns and indicator data

- price and consensus price forecast:
- business market valuation indicators:
Fundamental valuation:OPKO Health, Inc. (OPK)
Mass-produced product of OPKO Health Inc

OPKO Health, Inc. (OPK) diversification into diagnostics and veterinary medicine drives the dynamics of the Enterprise Value-to-Revenue (EV/Revenue) multiple. This indicator compares the market value of the business with its annual turnover, excluding the impact of debt load. The calculation is based on the ratio of Enterprise Value (EV) to sales, which reveals the asset's true fundamental attractiveness. A decrease in this metric through asset sales signals increasing reliability. The stock represents a growth business class with a moderate risk of overvaluation.

Competitor analysis for OPKO Health, Inc.

A (Agilent) - Company Value to Revenue Ratio|DGX (Quest Diagnostics) - Company Value to Revenue|Illumina Inc (ILMN) - EV/Sales Multiple|Company Value to Revenue EXAS|Revvity, Inc. (RVTY) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple BIO|NNNN (Anbio Biotechnology) - Business Value to Revenue|EV/Sales Multiple SHC (Sotera Health)|Quidel Corporation (QDEL) - Enterprise Value-to-Revenue Multiple|CareDx Inc - EV/Sales Multiple|Business Value to Revenue MRVI (Maravai)|FLGT: EV/Sales Multiple|LAB (Standard BioTools Inc.) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Cytek Biosciences Inc|Enterprise Value-to-Revenue Multiple OraSure OSUR|Company Value to Revenue XGN (Exagen Diagnostics)|Total Company Value-to-Revenue Ratio MDxHealth Inc.|Enterprise Value-to-Revenue Ratio Lucid Diagnostics, Inc. LUCD|Prenetics Global Ltd (PRE) - Enterprise Value-to-Revenue Multiple|Insight Molecular Diagnostics Inc - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple trinitybiotech.com|PRPH (ProPhase) - Company Value to Revenue|Company Value to Revenue Ratio AIMD|Company Value to Revenue CODX|Enterprise Value-to-Revenue Multiple heartsciences.com HSCS|Enterprise Value-to-Revenue Ratio Biomerica Inc. (BMRA)|Total Company Value-to-Revenue Ratio Cardio Diagnostics Holdings|EV/Sales Multiple ONCO (Onconetix Corporation)|Virax Biolabs Group (VRAX) - Enterprise Value-to-Revenue Multiple|bluejaydx.com - EV/Sales Multiple|Aspira Women's Health - Enterprise Value-to-Revenue Coefficient|AXDX (Accelerate Diagnostics) - Company Value to Revenue|Company Value to Revenue CENTOGENE, N.V.|Enterprise Value-to-Revenue Ratio enzo.com|EV/Sales Multiple Fresh2 Group Limited|EV/Sales Multiple GENE|23andMe Holding Co. - Company Value to Revenue Ratio|Psychemedics Inc - Company Value to Revenue